Six-year outcomes of a phase II study of human-tissue engineered blood vessels for peripheral arterial bypass
JVS-Vascular Science(2023)
摘要
The infection-resistant, off-the-shelf HAV could provide a durable alternative conduit in the arterial circuit setting to restore the lower extremity blood supply in patients with PAD, with remodeling into the recipient's own vessel over time. The HAV is currently being evaluated in seven clinical trials to treat PAD, vascular trauma, and as a hemodialysis access conduit.
更多查看译文
关键词
Arterial reconstruction,Bioengineered blood vessel,Human acellular vessel,Long-term outcomes,Peripheral artery disease
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要